Amyloid Precursor Protein (Protein|Antibody|cDNA Clone|ELISA Kit)

All Amyloid Precursor Protein reagents are produced in house and quality controlled, including 2 Amyloid Precursor Protein Antibody, 27 Amyloid Precursor Protein Gene, 1 Amyloid Precursor Protein Lysate, 5 Amyloid Precursor Protein Protein, 2 Amyloid Precursor Protein qPCR. All Amyloid Precursor Protein reagents are ready to use.

Recombinant Amyloid Precursor Protein proteins are expressed by HEK293 Cells, E. coli with fusion tags as C-human IgG1-Fc, N-GST & His.

Amyloid Precursor Proteinantibodies are validated with different applications, which are ELISA.

Amyloid Precursor ProteincDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each Amyloid Precursor Protein of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.

Amyloid Precursor Protein Protein (5)


Amyloid Precursor Protein Antibody (2)


Anti-Amyloid Precursor Protein Antibody


Application: ELISA

Clonality: PAb

Anti-Amyloid Precursor Protein Antibody


Application: ELISA

Clonality: PAb


Amyloid Precursor Protein cDNA Clone (27)


Amyloid Precursor Protein qPCR Primer (2)

Amyloid Precursor Protein Lysate (1)

Amyloid precursor protein (APP) is a type I transmembrane protein expressed in many tissues and concentrated in the synapses of neurons, and is suggested as a regulator of synapse formation and neural plasticity. APP can be processed by two different proteolytic pathways. In one pathway, APP is cleaved by β- and γ-secretase to produce the amyloid-β-protein (Aβ, Abeta, beta-amyloid) which is the principal component of the amyloid plaques, the major pathological hallmark of Alzheimer’s disease (AD), while in the other pathway, α-secretase is involved in the cleavage of APP whose product exerts antiamyloidogenic effect and prevention of the Aβ peptide formation. The aberrant accumulation of aggregated beta-amyloid peptides (Abeta) as plaques is a hallmark of AD neuropathology and reduction of Abeta has become a leading direction of emerging experimental therapies for the disease. Besides this pathological function of Abeta, recently published data reveal that Abeta also has an essential physiological role in lipid homeostasis. Cholesterol increases Abeta production, and conversely A beta production causes a decrease in cholesterol synthesis. Abeta may be part of a mechanism controlling synaptic activity, acting as a positive regulator presynaptically and a negative regulator postsynaptically. The pathological accumulation of oligomeric Abeta assemblies depresses excitatory transmission at the synaptic level, but also triggers aberrant patterns of neuronal circuit activity and epileptiform discharges at the network level. Abeta-induced dysfunction of inhibitory interneurons likely increases synchrony among excitatory principal cells and contributes to the destabilization of neuronal networks. There is evidence that beta-amyloid can impair blood vessel function. Vascular beta-amyloid deposition, also known as cerebral amyloid angiopathy, is associated with vascular dysfunction in animal and human studies. Alzheimer disease is associated with morphological changes in capillary networks, and soluble beta-amyloid produces abnormal vascular responses to physiological and pharmacological stimuli.